Lu AE58054
(Preusmjereno sa stranice LIXYCQPIKCLHMF-UHFFFAOYSA-N)
Lu AE58054 je potentan i selektivan antagonist 5-HT6 receptora. On je u razvoju kao augmentaciona terapija za tretman kognitivnih deficita vezanih za Alchajmerovu bolest i šizofreniju.[3][4][4]
(IUPAC) ime | |||
---|---|---|---|
2-(6-fluoro-1H-indol-3-il)-N-(3-(2,2,3,3,3-pentafluoropropoksi)benzil)etanamin | |||
Klinički podaci | |||
Identifikatori | |||
CAS broj | 467459-31-0 | ||
ATC kod | nije dodeljen | ||
PubChem[1][2] | 71587742 | ||
Hemijski podaci | |||
Formula | C20H19F5N2O | ||
Mol. masa | 398,37 g/mol | ||
SMILES | eMolekuli & PubHem | ||
| |||
Sinonimi | Lu-AE-58054 | ||
Farmakoinformacioni podaci | |||
Trudnoća | ? | ||
Pravni status |
References uredi
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ „U.S. Development Programs. - Lundbeck”.
- ↑ 4,0 4,1 „Search of: Lu AE58054 - List Results - ClinicalTrials.gov”.
Spoljašnje veze uredi
- Lundbeck expands its pipeline - initiating phase II clinical trials with a new compound for the treatment of schizophrenia Arhivirano 2011-07-09 na Wayback Machine-u
- Lundbeck initiates clinical phase II trials with Lu AE58054 as augmentation treatment in Alzheimer's disease Arhivirano 2010-02-04 na Wayback Machine-u